GE HealthCare, Stanford Medication Renew Analysis Collaboration

Editorial Team
2 Min Read


What You Ought to Know: 

GE HealthCare has renewed its analysis collaboration with Stanford Medication. A key intention of this renewed effort is the event and analysis of revolutionary whole physique PET/CT know-how, aiming to discover new scientific pathways and improve affected person outcomes by way of superior imaging options.

– The collaboration brings collectively the engineering experience of GE HealthCare with the scientific and analysis management of Stanford Medication to push the boundaries of what’s doable in molecular imaging.

This initiative is a part of GE HealthCare’s broader effort to collaborate with main healthcare establishments to reveal how whole physique PET/CT imaging can overcome boundaries which have beforehand hindered its widespread adoption past oncology. Researchers at Stanford Medication and engineers at GE HealthCare goal to advance a next-generation PET/CT system designed to offer new alternatives to enhance prognosis, staging, and therapeutic planning. The excessive sensitivity and spatial decision of the know-how are anticipated to create important scientific benefits.

Molecular imaging with PET/CT gives alternatives for precision care throughout varied illness states, together with:

  • Supporting theranostics in oncology for superior prostate most cancers therapy.
  • Aiding in beta-amyloid imaging for Alzheimer’s analysis.
  • Aiding in myocardial perfusion analysis for diagnosing coronary artery illness.

“This know-how is designed to supply a degree of sensitivity and spatial decision that may change how we design and conduct molecular imaging research,” provides Dr. Andrei Iagaru, Division Chief of Nuclear Medication and Molecular Imaging, Stanford Medication. “For instance, such technological traits can create alternatives to cut back anesthesia use in pediatric imaging by dramatically shortening scan instances and allow the exploration of dual-tracer research and early prognosis with far higher precision.”

Share This Article